Repurposing fusidic acid as an antimicrobial against enterococci with a low probability of resistance development.
Enterococcus faecalis
Enterococcus faecium
Fusidic acid
Repurposing
Treatment
Vancomycin-resistant enterococci
Journal
International microbiology : the official journal of the Spanish Society for Microbiology
ISSN: 1618-1905
Titre abrégé: Int Microbiol
Pays: Switzerland
ID NLM: 9816585
Informations de publication
Date de publication:
27 Mar 2024
27 Mar 2024
Historique:
received:
09
11
2023
accepted:
10
03
2024
revised:
26
02
2024
medline:
27
3
2024
pubmed:
27
3
2024
entrez:
27
3
2024
Statut:
aheadofprint
Résumé
Drug repurposing constitutes a strategy to combat antimicrobial resistance, by using agents with known safety, pharmacokinetics, and pharmacodynamics. Previous studies have implemented new fusidic acid (FA) front-loading-dose regimens, allowing higher serum levels than those achievable with ordinary doses. As susceptibility breakpoints are affected by serum level, we evaluated the repurposing of FA as an antimicrobial product against enterococci. FA minimum inhibitory concentrations (MICs) against standard enterococci strains; Enterococcus faecalis ATCC 29212 and Enterococcus faecium ATCC 27270 were 2 and 4 µg/mL, respectively. The MIC against 98 enterococcal clinical isolates was ≤ 8 µg/mL; all would be susceptible if categorized according to recalculated breakpoints (≥ 16 µg/mL), based on the serum level achieved using the front-loading regimen. FA administration in vivo, using the BALB/c mouse infection model, significantly reduced bacterial burden by two to three log
Identifiants
pubmed: 38532184
doi: 10.1007/s10123-024-00506-w
pii: 10.1007/s10123-024-00506-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Abadallah M, Zaki S, Sayed A, Erfan D (2007) Evaluation of secondary bacterial infection of skin diseases in Egyptian in & outppatients & their sensitivity to antimicrobials. Egypt Dermatol Online J 3(2):3
Abdelkareem MZ, Sayed M, Hassuna NA, Mahmoud MS, Abdelwahab SF (2017) Multi-drug-resistant Enterococcus faecalis among Egyptian patients with urinary tract infection. J Chemother 29(2):74–82. https://doi.org/10.1080/1120009X.2016.1182358
doi: 10.1080/1120009X.2016.1182358
Ali YM, Sim RB, Schwaeble W, Shaaban MI (2019) Enterococcus faecalis escapes complement-mediated killing via recruitment of complement factor H. J Infect Dis 220(6):1061–1070. https://doi.org/10.1093/infdis/jiz226
doi: 10.1093/infdis/jiz226
Alsanie WF, Felemban EM, Shafie A, Alhomrani M, Habeeballah H, Alsharif K, Farid MA (2019) The antimicrobial resistance and prevalence of Enterococcus species in Saudi Arabia. J Pure Appl Microbiol 13(4):2461–2470. https://doi.org/10.22207/JPAM.13.4.61
doi: 10.22207/JPAM.13.4.61
Aung M S, Urushibara N, Kawaguchiya M, Ohashi N, Hirose M, Kudo K, Tsukamoto N, Ito M and Kobayashi N (2023) Antimicrobial resistance, virulence factors, and genotypes of Enterococcus faecalis and Enterococcus faecium clinical isolates in Northern Japan: identification of optrA in ST480 E. faecalis. Antibiotics 12(1). https://doi.org/10.3390/antibiotics12010108
Boccella M, Santella B, Pagliano P, De Filippis A, Casolaro V, Galdiero M, Borrelli A, Capunzo M, Boccia G, Franci G (2021) Prevalence and antimicrobial resistance of enterococcus species: a retrospective cohort study in Italy. Antibiotics 10(12):1–9. https://doi.org/10.3390/antibiotics10121552
doi: 10.3390/antibiotics10121552
Bordo D, Argos P (1991) Suggestions for “safe” residue substitutions in site-directed mutagenesis. J Mol Biol Elsevier 217(4):721–729
doi: 10.1016/0022-2836(91)90528-E
Bourgogne A, Garsin DA, Qin X, Singh KV, Sillanpaa J, Yerrapragada S, Ding Y, Dugan-Rocha S, Buhay C, Shen H, Chen G, Williams G, Muzny D, Maadani A, Fox KA, Gioia J, Chen L, Shang Y, Arias CA, Nallapareddy SR, Zhao M, Prakash VP, Chowdhury S, Jiang H, Gibbs RA, Murray BE, Highlander SK, Weinstock GM (2008) Large scale variation in Enterococcus faecalis illustrated by the genome analysis of strain OG1RF. Genome Biol 9(7):1–16. https://doi.org/10.1186/gb-2008-9-7-r110
doi: 10.1186/gb-2008-9-7-r110
Bulitta JB, Okusanya OO, Forrest A, Bhavnani SM, Clark K, Still JG, Fernandes P, Ambroseb PG (2013) Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance. Antimicrob Agents Chemother 57(1):498–507. https://doi.org/10.1128/AAC.01354-12
doi: 10.1128/AAC.01354-12
Cama A, Quon MJ, De la Luz Sierra M, Taylor SI (1992) Substitution of isoleucine for methionine at position 1153 in the beta-subunit of the human insulin receptor. A mutation that impairs receptor tyrosine kinase activity, receptor endocytosis, and insulin action. J Biol Chem 267(12):8383–8389 (Elsevier)
doi: 10.1016/S0021-9258(18)42456-8
Centers for Disease Control and Prevention (2022) ‘Covid-19 U.S. impact on antimicrobial resistance. Atlanta, GA: U.S. Dep Health Hum Serv CDC 2022:1–44
Clinical and Laboratory Standards Institute (2015) Performance standards for antimicrobial disk susceptibility tests; approved standard. 12th Edition. CLSI document M02-A12. Clinical and Laboratory Standards Institute, USA
Clinical and Laboratory Standards Institute (2018) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 11th Edition, CLSI standard M07. Clinical and Laboratory Standards Institute, USA
Clinical and Laboratory Standards Institute (2023a) Performance standards for antimicrobial susceptibility testing, 33rd Edition, CLSI supplement M100. Clinical and Laboratory Standards Institute, USA
Clinical and Laboratory Standards Institute (2023b) Development of in vitro susceptibility testing criteria, breakpoints and quality control parameters. 6th Edition. CLSI guidelines M23. Clinical and Laboratory Standards Institute, USA
Coombs G W, Daley D A, Yee N W T, Shoby P and Mowlaboccus S (2022) Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2020. Commun Dis Intell (2018) 46. https://doi.org/10.33321/cdi.2022.46.17
Cui L, Ma X, Sato K, Okuma K, Tenover FC, Mamizuka EM, Gemmell CG, Kim MN, Ploy MC, El Solh N, Ferraz V, Hiramatsu K (2003) Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 41(1):5–14. https://doi.org/10.1128/JCM.41.1.5-14.2003
doi: 10.1128/JCM.41.1.5-14.2003
Cushnie TPT, O’Driscoll NH, Lamb AJ (2016) Morphological and ultrastructural changes in bacterial cells as an indicator of antibacterial mechanism of action. Cell Mol Life Sci 73(23):4471–4492. https://doi.org/10.1007/s00018-016-2302-2
doi: 10.1007/s00018-016-2302-2
De S, Kaur G, Roy A, Dogra G, Kaushik R, Yadav P, Singh R, Datta TK, Goswami SL (2010) ‘A simple method for the efficient isolation of genomic DNA from Lactobacilli isolated from traditional indian fermented milk (dahi)’, Indian journal of microbiology. Springer 50:412–418
Dubey KK, Indu, Sharma M (2020) Reprogramming of antibiotics to combat antimicrobial resistance. Arch Pharm 353(11). https://doi.org/10.1002/ardp.202000168
Dutka-Malen S, Evers S, Courvalin P (1995) Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J Clin Microbiol Am Soc Microbiol 33(1):24–27. https://doi.org/10.1128/jcm.33.1.24-27.1995
doi: 10.1128/jcm.33.1.24-27.1995
EUCAST (2021) Setting breakpoints for new antimicrobial agents, EUCAST SOP 1.4. http://www.eucast.org . Accessed 20 Feb 2024
EUCAST (2022) Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0. http://www.eucast.org . Accessed 20 Feb 2024
Fernandes P (2016) Fusidic acid: a bacterial elongation factor inhibitor for the oral treatment of acute and chronic staphylococcal infections. Cold Spring Harb Perspect Med 6(1):1–17. https://doi.org/10.1101/cshperspect.a025437
doi: 10.1101/cshperspect.a025437
Fernández L, Hancock REW (2012) Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev Am Soc Microbiol 25(4):661–681
doi: 10.1128/CMR.00043-12
Garcia Chavez M, Garcia A, Lee HY, Lau GW, Parker EN, Komnick KE, Hergenrother PJ (2021) Synthesis of fusidic acid derivatives yields a potent antibiotic with an improved resistance profile. ACS Infect Dis 7(2):493–505. https://doi.org/10.1021/acsinfecdis.0c00869
doi: 10.1021/acsinfecdis.0c00869
Gupta SK, Pfeltz RF, Wilkinson BJ, Gustafson JE (2022) Transcriptomic and metabolomic analysis of a fusidic acid-selected fusa mutant of Staphylococcus aureus. Antibiotics 11(8):1–12. https://doi.org/10.3390/antibiotics11081051
doi: 10.3390/antibiotics11081051
Hajikhani B, Goudarzi M, Kakavandi S, Amini S, Zamani S, van Belkum A, Goudarzi H, Dadashi M (2021) ‘The global prevalence of fusidic acid resistance in clinical isolates of Staphylococcus aureus: a systematic review and meta-analysis. Antimicrob Resist Infect Control BioMed Central 10(1):1–14. https://doi.org/10.1186/s13756-021-00943-6
doi: 10.1186/s13756-021-00943-6
Hashem YA, Amin HM, Essam TM, Yassin AS, Aziz RK (2017) Biofilm formation in enterococci: genotype-phenotype correlations and inhibition by vancomycin. Sci Rep 7(1):5733. https://doi.org/10.1038/s41598-017-05901-0 . (Nature Publishing Group UK London)
doi: 10.1038/s41598-017-05901-0
Howden BP, Grayson ML (2006) Dumb and dumber - the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis 42(3):394–400. https://doi.org/10.1086/499365
doi: 10.1086/499365
Ibrahim KA, El-Ashrey MK, Kashef MT, Helmy OM (2023) Alanine racemase a promising Helicobacter pylori drug target inhibited by propanoic acid. Microbes Infect. Institut Pasteur, 105167. https://doi.org/10.1016/j.micinf.2023.105167 .
Jones RN, Mendes RE, Sader HS, Castanheira M (2011) In vitro antimicrobial findings for fusidic acid tested against contemporary (2008–2009) gram-positive organisms collected in the United States. Clin Infect Dis 52(SUPPL. 7). https://doi.org/10.1093/cid/cir163
Kateete DP, Edolu M, Kigozi E, Kisukye J, Baluku H, Mwiine FN, Najjuka CF (2019) Species, antibiotic susceptibility profiles and van gene frequencies among enterococci isolated from patients at Mulago National Referral Hospital in Kampala, Uganda. BMC Infect Dis BMC Infect Dis 19(1):1–9. https://doi.org/10.1186/s12879-019-4136-7
doi: 10.1186/s12879-019-4136-7
Kusanya OO, Tsuji BT, Bülitta JB, Forrest A, Bulik CC, Bhavnani SM, Fernandes P, Ambrose PG (2011) Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection. Diagn Microbiol Infect Dis 70(1):101–111. https://doi.org/10.1016/j.diagmicrobio.2011.03.001 . (Elsevier Inc.)
doi: 10.1016/j.diagmicrobio.2011.03.001
Lerminiaux NA, Cameron ADS (2019) Horizontal transfer of antibiotic resistance genes in clinical environments. Can J Microbiol 65(1):34–44. https://doi.org/10.1139/cjm-2018-0275
doi: 10.1139/cjm-2018-0275
Li G, Walker MJ, De Oliveira DMP (2023) Vancomycin resistance in Enterococcus and Staphylococcus aureus. Microorganisms 11(1). https://doi.org/10.3390/microorganisms11010024
MacGowan AP, Wise R (2001) Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother 48(SUPPL. 1):17–28. https://doi.org/10.1093/jac/48.suppl_1.17
doi: 10.1093/jac/48.suppl_1.17
Miller WR, Tran TT, Diaz L, Rios R, Khan A, Reyes J, Prater AG, Panesso D, Shamoo Y, Arias CA (2019) LiaR-independent pathways to daptomycin resistance in Enterococcus faecalis reveal a multilayer defense against cell envelope antibiotics. Mol Microbiol 111(3):811–824. https://doi.org/10.1111/mmi.14193
doi: 10.1111/mmi.14193
Nakamura M, Kawada H, Uchida H, Takagi Y, Obata S, Eda R, Hanaki H, Kitasato H (2021) Single nucleotide polymorphism leads to daptomycin resistance causing amino acid substitution-T345I in MprF of clinically isolated MRSA strains. PLoS One 16(1 January):1–15. https://doi.org/10.1371/journal.pone.0245732
doi: 10.1371/journal.pone.0245732
Navarro MOP, Simionato AS, Pérez JCB, Barazetti AR, Emiliano J, Niekawa ETG, de Lima Andreata MF, Modolon F, Dealis ML, de Almeida Araújo EJ (2019) Fluopsin C for treating multidrug-resistant infections: in vitro activity against clinically important strains and in vivo efficacy against carbapenemase-producing Klebsiella pneumoniae. Front Microbiol 10:2431 (Frontiers Media SA)
doi: 10.3389/fmicb.2019.02431
Ohmura T, Ueda T, Hashimoto Y, Imoto T (2001) Tolerance of point substitution of methionine for isoleucine in hen egg white lysozyme. Protein Eng 14(6):421–425 (Oxford University Press)
doi: 10.1093/protein/14.6.421
Onyeji CO, Nicolau DP, Nightingale CH, Bow L (2000) ‘Modulation of efficacies and pharmacokinetics of antibiotics by granulocyte colony-stimulating factor in neutropenic mice with multidrug-resistant Enterococcus faecalis infection. J Antimicrob Chemother 46(3):429–436 (Oxford University Press)
doi: 10.1093/jac/46.3.429
Payne AJ, Neal LM, Knoll LJ (2013) Fusidic acid is an effective treatment against Toxoplasma gondii and Listeria monocytogenes in vitro, but not in mice. Parasitol Res 112(11):3859–3863. https://doi.org/10.1007/s00436-013-3574-1
doi: 10.1007/s00436-013-3574-1
Queipo-Ortuño MI, De Dios CJ, Macias M, Bravo MJ, Morata P (2008) Preparation of bacterial DNA template by boiling and effect of immunoglobulin g as an inhibitor in real-time PCR for serum samples from patients with brucellosis. Clin Vaccine Immunol 15(2):293–296. https://doi.org/10.1128/CVI.00270-07
doi: 10.1128/CVI.00270-07
Rodríguez C, Alonso-calleja C, Garc C, Carballo J, Capita R (2022) Bactericidal concentration ( MBC ) for twelve antimicrobials. Biology 11(Mic):46. https://doi.org/10.3390/biology11010046
doi: 10.3390/biology11010046
Rolston KV, Wang W, Nesher L, Smith JR, Rybak MJ, Prince RA (2017) Time-kill determination of the bactericidal activity of telavancin and vancomycin against clinical methicillin-resistant Staphylococcus aureus isolates from cancer patients. Diagn Microbiol Infect Dis 87(4):338–342. https://doi.org/10.1016/j.diagmicrobio.2016.12.010
doi: 10.1016/j.diagmicrobio.2016.12.010
Tag ElDein MA, Yassin AS, El-Tayeb O, Kashef MT (2021) ‘Chlorhexidine leads to the evolution of antibiotic-resistant Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 40(11):2349–2361. https://doi.org/10.1007/s10096-021-04292-5 . (Springer, Berlin Heidelberg)
doi: 10.1007/s10096-021-04292-5
Toma E, Barriault D (1995) Antimicrobial activity of fusidic acid and disk diffusion susceptibility testing criteria for gram-positive cocci. J Clin Microbiol 33(7):1712–1715. https://doi.org/10.1128/jcm.33.7.1712-1715.1995
doi: 10.1128/jcm.33.7.1712-1715.1995
Tsuchiya K, Cao Y-Y, Kurokawa M, Ashino K, Yomo T, Ying B-W (2018) A decay effect of the growth rate associated with genome reduction in Escherichia coli. BMC Microbiol 18:1–10 (Springer)
doi: 10.1186/s12866-018-1242-4
Tsuji BT, Okusanya OO, Bulitta JB, Forrest A, Bhavnani SM, Fernandez PB, Ambrose PG (2011) Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead. Clin Infect Dis 52(suppl 7):S513–S519. https://doi.org/10.1093/cid/cir166 . (Oxford University Press)
doi: 10.1093/cid/cir166
World Health Organization (2017) WHO publishes list of bacteria for which new antibiotics are urgently needed. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed . Accessed 25 Nov 2022
Yin S, Rao G, Wang J, Luo L, He G, Wang C, Ma C, Luo X, Hou Z, Xu G (2015) Roemerine improves the survival rate of septicemic BALB/c mice by increasing the cell membrane permeability of staphylococcus aureus. PLoS One 10(11):1–13. https://doi.org/10.1371/journal.pone.0143863
doi: 10.1371/journal.pone.0143863
Zhang H, Zhang X, Liang S, Wang J, Zhu Y, Zhang W, Liu S, Schwarz S, Xie F (2023) ‘Bactericidal synergism between phage endolysin Ply2660 and cathelicidisn LL-37 against vancomycin-resistant Enterococcus faecalis biofilms. npj Biofilms Microbiomes 9(1):16. https://doi.org/10.1038/s41522-023-00385-5 . (Nature Publishing Group UK London)
doi: 10.1038/s41522-023-00385-5